Suppression of stent-induced tissue hyperplasia in rats by using small interfering RNA to target matrix...

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Gastroenterology

Background:

• Stent placement in the esophagus can lead to tissue hyperplasia, a significant clinical complication.
• Matrix metalloproteinase-9 (MMP-9) is implicated in the pathogenesis of tissue hyperplasia.
• Targeting MMP-9 offers a potential therapeutic strategy to mitigate stent-induced hyperplasia.

Purpose of the Study:

• To evaluate the efficacy of small interfering RNA (siRNA) targeting MMP-9 in suppressing stent-induced esophageal tissue hyperplasia.
• To assess the therapeutic potential of an MMP-9 siRNA/Chol-R9 complex in a rat esophageal model.

Main Methods:

• In vitro evaluation of candidate siRNA efficacy in rat glial cells.
• Establishment of a rat esophageal stent model with four experimental groups: stent only, MMP-9 siRNA treatment, control treatment, and no treatment.
• Assessment of tissue hyperplasia, granulation tissue percentage and area, and MMP-9 levels at 3 weeks post-stenting.

Main Results:

• The most potent MMP-9 siRNA was identified and utilized.
• Rats treated with MMP-9 siRNA/Chol-R9 complex exhibited significantly reduced tissue hyperplasia compared to the control stent group.
• A significant decrease in MMP-9 levels was observed in the treatment group, correlating with reduced hyperplasia.

Conclusions:

• MMP-9 siRNA, delivered via Chol-R9 complex, is effective in inhibiting stent-induced tissue hyperplasia in a rat esophageal model.
• This approach represents a promising therapeutic strategy for managing esophageal hyperplasia following stent placement.